Document Detail

The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients.
MedLine Citation:
PMID:  16146492     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Glatiramer acetate (GA) is routinely used in multiple sclerosis (MS) patients who cannot tolerate or fail to respond to beta-interferon (IFN-beta). The aim of this study was to assess the efficacy and tolerability of GA in these patients. METHODS: Fifteen relapsing-remitting MS patients who had discontinued IFN-beta therapy due to side effects were included in this open, 1-year prospective study. Neurologic examinations and laboratory assessments were performed every 3 months. The induction of MxA protein production was also evaluated. RESULTS: Eleven of fifteen patients (73%) tolerated GA well whereas four patients (27%) discontinued treatment due to side effects. The relapse rate reduced from 1.86 per year to 0.91 per year. Neither laboratory abnormalities nor MxA protein induction was found. CONCLUSION: GA can be considered as a good treatment alternative to IFN-beta-intolerant MS patients. However, some patients were not able to use available immunomodulative treatments, which emphasizes the need for new therapeutic options. The lack of MxA protein induction confirms the different mechanisms of action of GA and IFN-beta.
A M Vallittu; J Peltoniemi; I Elovaara; H Kuusisto; M Färkkilä; J Multanen; J P Erälinna
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Acta neurologica Scandinavica     Volume:  112     ISSN:  0001-6314     ISO Abbreviation:  Acta Neurol. Scand.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-09-08     Completed Date:  2005-10-25     Revised Date:  2006-08-16    
Medline Journal Info:
Nlm Unique ID:  0370336     Medline TA:  Acta Neurol Scand     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  234-7     Citation Subset:  IM    
Department of Virology, University of Turku, Turku, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / adverse effects
Immunosuppressive Agents / administration & dosage*,  adverse effects
Interferon-beta / adverse effects
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Peptides / administration & dosage*,  adverse effects
Prospective Studies
Treatment Outcome
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Immunosuppressive Agents; 0/Peptides; 0/copolymer 1; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cognitive performance in cryptogenic epilepsy.
Next Document:  Analysis of Chlamydia pneumoniae-specific oligoclonal bands in multiple sclerosis and other neurolog...